2
Announcements
Trials
Browse
Landscape
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Breast
1
Conditions
Neoplasms
4
Prostatic Neoplasms
3
Lung Neoplasms
2
Carcinoma, Renal Cell
2
Weight Loss
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Sleep Apnea Syndromes
1
Sezary Syndrome
1
Sarcoma
1
Recurrence
1
Overweight
1
Obesity, Morbid
1
Obesity
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Multiple Myeloma
1
Lymphoma, T-Cell, Cutaneous
1
Hypertension
1
Hyperlipidemias
1
Hemangioma
1
Gastroesophageal Reflux
1
Eczema
1
Disease
1
Digestive System Diseases
1
Diabetes Mellitus, Type 2
1
Diabetes Mellitus
1
Dermatitis, Atopic
1
Collagen Diseases
1
Interventions
pembrolizumab
161
Carboplatin
145
Paclitaxel
125
Cyclophosphamide
94
130-nm albumin-bound paclitaxel
66
Capecitabine
64
Gemcitabine
54
Doxorubicin
50
Albumin-Bound Paclitaxel
45
Taxes
42
atezolizumab
41
Cisplatin
38
sacituzumab govitecan
34
Nivolumab
34
olaparib
32
Epirubicin
32
Specimen Handling
28
Docetaxel
28
eribulin
27
Bevacizumab
26
durvalumab
25
Drug Therapy
25
Biopsy
24
camrelizumab
23
Magnetic Resonance Spectroscopy
22
toripalimab
19
Radiotherapy
17
spartalizumab
16
Everolimus
15
veliparib
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Urine Specimen Collection
×
Clear all
NCT04268693
2022-11-17
EDC-TNBC
George Washington University
Withdrawn